Bringing the Oncology Community Together

Dr. Pierluigi Porcu Discusses CTCL Research

Pierluigi Porcu, MD,
Published Online: Monday, December 30, 2013
Pierluigi Porcu, MD, associate professor of internal medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), discusses early research into the development of cutaneous T cell lymphoma (CTCL).

At the 2013 ASH Annual Meeting and Exposition, an abstract was presented by Porcu and his team about an animal model of CTCL. Porcu explains that CTCL is a malignant blood disorder that affects 15,000-20,000 patients in the United States. The disease manifests predominately in the skin with no known cause.

Porcu says the animal model that was presented at ASH is designed to discover the early steps of the development of the disease and will help researchers study new treatments.

Some of the results from the animal model have been reproduced in human patients, Porcu says. For example, the mice overexpress the cytokine interleukin-15, which causes an overproliferation of T cells. This has also been observed in human samples, providing a proof of concept that both the human model and the mouse model have parallel mechanisms of growth.

Related Articles
FDA Approves Siltuximab for Multicentric Castleman’s Disease
The FDA has approved the anti-IL-6 chimeric monoclonal antibody siltuximab as a treatment for HIV- and HHV-8-negative patients with multicentric Castleman’s disease.
Treatment of MDS Refractory to Hypomethylating Agent
Panelists discuss the limited number of treatment options that exist for patients with myelodysplastic syndromes who progress on hypomethylating agents, such as azacitidine and decitabine.
Role of Radiation Therapy in Hodgkin Lymphoma
Panelists discuss the evolving role of radiation therapy in Hodgkin lymphoma and whether new approaches lessen the long-term toxicity traditionally associated with this treatment modality.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.